| Literature DB >> 31146791 |
Mekonnen Sisay1, Teshager Worku2, Dumessa Edessa3.
Abstract
BACKGROUND: Wound infections are responsible for significant human morbidity and mortality worldwide. Specifically, surgical site infections are the third most commonly reported nosocomial infections accounting approximately a quarter of such infections. This systematic review and meta-analysis is, therefore, aimed to determine microbial profiles cultured from wound samples and their antimicrobial resistance patterns in Ethiopia.Entities:
Keywords: Antimicrobial resistance; Bacteria; Ethiopia; Wound infections
Mesh:
Substances:
Year: 2019 PMID: 31146791 PMCID: PMC6543595 DOI: 10.1186/s40360-019-0315-9
Source DB: PubMed Journal: BMC Pharmacol Toxicol ISSN: 2050-6511 Impact factor: 2.483
Fig. 1PRISMA flow diagram depicting the selection process
Quality assessment of studies using JBI’s critical appraisal tools designed for cross-sectional studies
| Studies | JBI’s critical appraisal questions | Overall score | Include | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | |||
| Abraham and Wamisho., 2009 | Y | Y | Y | Y | Y | Y | Y | U | N | 7 | ✓ |
| Alebachew et al., 2012 | N | Y | N | Y | N | Y | Y | Y | Y | 6 | ✓ |
| Asres et al., 2017 | N | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Azene et al., 2011 | U | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Bitew et al., 2018 | U | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Desalegn et al., 2014 | Y | Y | Y | Y | Y | Y | Y | N | Y | 8 | ✓ |
| Dessie et al., 2016 | U | Y | N | Y | Y | Y | Y | Y | Y | 7 | ✓ |
| Gelaw et al., 2014 | U | Y | N | Y | Y | Y | Y | Y | Y | 7 | ✓ |
| Godebo et al., 2013 | U | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Guta et al., 2014 | N | Y | N | Y | Y | Y | Y | Y | Y | 7 | ✓ |
| Hailu et al., 2016 | U | Y | Y | Y | Y | Y | Y | N | Y | 7 | ✓ |
| Kahsay et al., 2014 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 | ✓ |
| Kiflie et al., 2018 | Y | Y | N | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Lema et al., 2012 | N | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Mama et al., 2014 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 | ✓ |
| Mengesha et al., 2014 | Y | Y | N | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Mohammed et al., 2014 | N | Y | N | Y | Y | Y | Y | Y | Y | 7 | ✓ |
| Mulu et al., 2006 | U | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Mulu et al., 2017 | U | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| Sewnet et al., 2013 | N | Y | N | Y | Y | Y | Y | Y | Y | 7 | ✓ |
| Tekie, 2008 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 | ✓ |
Y Yes, N No, U Unclear, Q Question. Overall score is calculated by counting the number of Ys in each row
Q1 = Was the sample frame appropriate to address the target population? Q2 = Were study participants sampled in an appropriate way? Q3 = Was the sample size adequate? Q4 = Were the study subjects and the setting described in detail? Q5 = Was the data analysis conducted with sufficient coverage of the identified sample? Q6 = Were valid methods used for the identification of the condition? Q7 = Was the condition measured in a standard, reliable way for all participants? Q8 = Was there appropriate statistical analysis? Q9 = Was the response rate adequate, and if not, was the low response rate managed appropriately?
Characteristics of included studies describing the magnitude of culture positive wound samples and microbial profiles of clinical relevant bacterial isolates in Ethiopia (2000–2018)
| Studies | Year of publication | Study setting | Total patients (M/F ratio) | Study characteristics | Wound samples | Culture positive | No of isolates | Gram-positive | Gram -negative | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||||||||
| Abraham and Wamisho [ | 2009 | TASH, AA | 191 (158/33) | Fracture in-and outpatients | 200 | 196 | 162 | 24 | 12 | 17 | 16 | 12 | 6 |
| Alebachew et al. [ | 2012 | Yekatit 12 hospital | 114 (58/56) | Burn in-and outpatients | 114 | 95 | 114 | 65 | ND | ND | ND | ND | ND |
| Asres et al. [ | 2017 | TASH, AA | 197 (118/79) | Postoperative in-and outpatients | 197 | 149 | 168 | 56 | 19 | 24 | 8 | 15 | 2 |
| Azene et al. [ | 2011 | Dessie regional laboratory | 12599 (368/231) | Outpatients with any wound | 599 | 422 | 500 | 208 | 9 | 82 | 92 | 12 | 55 |
| Bitew et al. [ | 2018 | Arsho medical laboratory | 366 (213/153) | Both in-and Patients with wound | 366 | 271 | 271 | 110 | 11 | 49 | 14 | 12 | 7 |
| Desalegn et al. [ | 2014 | Hawassa TRH | 194 (116/78) | Post-surgical in and outpatients | 194 | 138 | 177 | 66 | 6 | 45 | 18 | 24 | 18 |
| Dessie et al. [ | 2016 | St. Paul and Yekatit 12 hosp. | 107 (56/51) | Surgical inpatients | 107 | 90 | 104 | 19 | 4 | 24 | 6 | 10 | 1 |
| Gelaw et al. [ | 2014 | UoG TH | 42 (27/15) | Surgical inpatients | 142 | 42 | 49 | 11 | 4 | 6 | 3 | 10 | 9 |
| Godebo et al. [ | 2013 | JUSH | NS | Out/inpatients with wound | 322 | 310 | 384 | 73 | 14 | 30 | 74 | 46 | 107 |
| Guta et al. [ | 2014 | HUTRH | 100 (37/63) | Surgical inpatients | 100 | 92 | 177 | 45 | 26 | 30 | 16 | 32 | 12 |
| Hailu et al. [ | 2016 | Bahir Dar RHRL | 234 (131/103) | Both in-and outpatients with wound | 380 | 234 | 234 | 100 | ND | 33 | 26 | 20 | 22 |
| Kahsay et al. [ | 2014 | DMRH | 184 (61/123) | Surgical inpatients | 184 | 73 | 184 | 72 | ND | ND | ND | ND | ND |
| Kiflie et al. [ | 2018 | UoG TH | 107 (0/107 | Women with cesarean section or episiotomy | 107 | 90 | 101 | 42 | 13 | 20 | 1 | 14 | 1 |
| Lema et al. [ | 2012 | Selected Hospitals, AA | 245 (157/88) | In-and outpatients with leprosy | 245 | 222 | 298 | 68 | 18 | 14 | 7 | 2 | 47 |
| Mama et al. [ | 2014 | JUSH | 150 (107/43) | In/outpatients with wound | 150 | 131 | 145 | 47 | 21 | 29 | 11 | 14 | 23 |
| Mengesha et al. [ | 2014 | Ayder TRH | 128 (98/30) | Surgical inpatients | 128 | 96 | 123 | 40 | 18 | 6 | 11 | 29 | 15 |
| Mohammed et al. [ | 2014 | UoG RH | 137 (81/56) | In/outpatients with wound | 137 | 115 | 136 | 39 | 17 | 8 | 8 | 17 | 6 |
| Mulu et al. [ | 2006 | UoGTH | NS | In/outpatients with wound | 151 | 79 | 79 | 51 | ND | 8 | ND | 7 | 3 |
| Mulu et al. [ | 2017 | DMRH | 238 (NS) | In/outpatients with wound | 238 | 115 | 90 | 70 | ND | 5 | 6 | 1 | 3 |
| Sewnet et al. [ | 2013 | Yekatit 12 hospital | 50 (30/20) | In/outpatients with burn case | 50 | 21 | 47 | 16 | 6 | ND | 15 | 1 | 4 |
| Tekie [ | 2008 | TASH | 173 (97/76) | Outpatients with surgical wound | 173 | 31 | 55 | 14 | 11 | 7 | 8 | 4 | 2 |
| Total | 4284 | 3012 | 3598 | ||||||||||
M Male, F Female, CoNS Coagulase negative Staphylococci, ND Not determined, JUSH Jimma University Specialized Hospital, UoGTH University of Gondar Teaching Hospital, Hawassa University Teaching and Referral Hospital, CS Cross-sectional, R Retrospective, TASH Tikur Anbesa Specialized Hospital, AA Addis Ababa, DMRH Debre Markos Referral Hospital, NS Not specified
Antimicrobial resistance patterns of clinically relevant bacterial isolates from wound infection in Ethiopia
| Types of Bacteria | Studies | Number of isolates | Number of isolates resistant to | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMO | AMC | AMP | CIP | CRO | SXT | ERY | GEN | MET | |||
|
| Abraham and Wamisho | 24 | 9 | 6 | 20 | 4 | 2 | 6 | 2 | 3 | 5 |
| Alebachew et al | 66 | – | 22 | – | – | 23 | – | 9 | – | 51 | |
| Asres et al. | 56 | – | 9 | – | 7 | – | 19 | 9 | 7 | 6 | |
| Azene et al | 208 | 165 | – | – | 18 | 37 | 140 | 72 | 26 | 22 | |
| Bitew et al | 110 | – | – | – | 7 | – | 30 | 70 | 2 | – | |
| Kiflie et al | 42 | 28 | – | 30 | – | 15 | 26 | – | – | 22 | |
| Desalegn et al | 66 | 20 | 63 | 26 | 54 | 37 | 29 | 26 | – | ||
| Dessie et al | 19 | – | – | – | 3 | – | 4 | 4 | 3 | – | |
| Godebo et al | 73 | – | – | 67 | 10 | 15 | 44 | 58 | 12 | 57 | |
| Guta et al | 45 | 45 | – | – | – | 16 | – | – | 9 | – | |
| Hailu et al | NDA | – | – | – | 5(67) | – | 16 (94) | 30 (96) | – | 20 (95) | |
| Kahsay et al | 73 | 13 | – | 13 | – | – | 1 | – | 9 | 36 | |
| Lema et al | 68 | 45 | 8 | 58 | 6 | – | 23 | 20 | 5 | 50 | |
| Mama et al | 47 | – | – | 45 | 2 | 7 | 3 | 7 | 2 | – | |
| Mengesha et al | 40 | 37 | 20 | 36 | – | 36 | – | 9 | 4 | 34 | |
| Mohammed et al | 39 | 34 | – | – | 8 | 8 | 15 | 24 | 7 | 30 | |
| Mulu et al., 2006 | 51 | – | – | 28 | – | – | 18 | – | – | – | |
|
| Abraham and Wamisho | 12 | 1 | – | 4 | 1 | 1 | – | 1 | 2 | |
| Asres et al. | 19 | – | 15 | – | 5 | – | 14 | 11 | 12 | ||
| Kiflie et al | 13 | 11 | – | 11 | – | 5 | 8 | – | – | ||
| Desalegn et al | 6 | – | 3 | 6 | 3 | 6 | 3 | 3 | 3 | ||
| Dessie et al | 4 | – | – | – | 4 | – | 3 | 3 | 3 | ||
| Godebo et al | 14 | – | – | 9 | 0 | 2 | 5 | 0 | 0 | ||
| Guta et al | 26 | 4 | – | – | – | 13 | – | – | 13 | ||
| Lema et al | 18 | 6 | – | 12 | 1 | – | 9 | 9 | 3 | ||
| Mama et al | 21 | – | – | 19 | 5 | 6 | 3 | 8 | 4 | ||
| Mengesha et al | 18 | 16 | 14 | 14 | – | 13 | – | 9 | 9 | ||
| Mohammed et al | 16 | 13 | – | – | 3 | 8 | 7 | 8 | 3 | ||
|
| Abraham and Wamisho | 17 | 8 | 4 | 7 | 1 | 2 | 5 | – | 2 | |
| Asres et al. | 24 | 20 | 14 | – | 5 | – | 15 | – | 7 | ||
| Azene et al | 82 | 70 | – | – | 21 | 55 | 55 | 43 | 12 | ||
| Bitew et al | 49 | – | 35 | 35 | 5 | 10 | 22 | – | 5 | ||
| Kiflie et al | 20 | 14 | – | 16 | 4 | 12 | 10 | – | 7 | ||
| Desalegn et al | 45 | – | 21 | 45 | 18 | 18 | 27 | – | 21 | ||
| Dessie et al | 24 | – | 17 | 23 | 16 | 20 | – | – | 13 | ||
| Godebo et al | 30 | – | – | 23 | 1 | 20 | 6 | – | 0 | ||
| Guta et al | 30 | 20 | – | – | – | 10 | – | – | 0 | ||
| Hailu et al | NDA | – | 24 (33) | 31 (33) | 15 (33) | 6 (24) | 23 (30) | – | 18 (33) | ||
| Lema et al | 14 | 10 | 7 | 9 | – | – | 9 | – | – | ||
| Mama et al | 29 | – | – | 29 | 10 | 18 | 16 | – | 15 | ||
| Mengesha et al | 6 | 4 | 6 | 6 | 1 | 4 | – | 2 | – | ||
| Mohammed et al | 8 | – | – | 6 | 3 | 1 | 4 | – | 1 | ||
| Mulu et al., 2006 | 8 | – | – | 7 | – | – | 5 | – | – | ||
|
| Abraham and Wamisho | 16 | 13 | 13 | 14 | 0 | 5 | 11 | – | 2 | |
| Asres et al. | 8 | 8 | 7 | – | 1 | – | 7 | – | 2 | ||
| Azene et al | 92 | 76 | – | – | 4 | 47 | 71 | 83 | 7 | ||
| Bitew et al | 14 | – | 14 | 14 | 1 | 11 | 9 | – | 1 | ||
| Desalegn et al | 18 | – | 18 | 18 | 0 | 18 | 12 | – | 9 | ||
| Dessie et al | 6 | – | 6 | 6 | 2 | 5 | – | – | 0 | ||
| Godebo et al | 74 | – | – | 72 | 4 | 7 | 65 | – | 8 | ||
| Guta et al | 16 | 16 | – | – | – | 8 | – | – | 8 | ||
| Hailu et al | NDA | – | – | – | 5 (26) | – | 3 (9) | – | 7 (23) | ||
| Lema et al | 7 | 6 | 7 | 6 | – | – | 7 | – | 1 | ||
| Mama et al | 11 | – | – | 11 | – | 7 | 8 | – | 2 | ||
| Mengesha et al | 11 | 11 | 11 | 11 | 9 | 11 | – | 3 | – | ||
| Mohammed et al | 8 | – | – | – | 3 | 3 | – | – | 3 | ||
| Tekie | 8 | – | – | – | 6 | 4 | 7 | – | 3 | ||
|
| Abraham and Wamisho | 12 | 8 | 4 | 12 | 0 | 3 | 3 | – | 3 | |
| Asres et al. | 15 | 14 | 12 | – | 4 | 13 | 13 | – | 9 | ||
| Azene et al | 12 | 12 | – | – | – | – | 8 | – | 0 | ||
| Bitew et al | 12 | – | 12 | 12 | 2 | 7 | 5 | – | 2 | ||
| Kiflie et al | 14 | 14 | – | 14 | 2 | 8 | 9 | – | 3 | ||
| Desalegn et al | 24 | – | 12 | 21 | 15 | 21 | 21 | – | 24 | ||
| Dessie et al | 10 | – | 10 | 10 | 2 | 9 | – | – | 4 | ||
| Godebo et al | 46 | – | – | 32 | 13 | 13 | 30 | – | 13 | ||
| Guta et al | 32 | 25 | – | – | – | 9 | – | – | 12 | ||
| Hailu et al | NDA | – | 10 (20) | 15 (20) | 4 (20) | 2 (18) | 8 (20) | – | 11 (18) | ||
| Mama et al | 14 | – | – | 14 | 5 | 10 | 12 | – | 9 | ||
| Mengesha et al | 29 | 29 | 19 | 26 | 11 | 25 | – | 13 | 8 | ||
| Mohammed et al | 17 | – | – | 16 | 10 | 9 | 11 | – | 5 | ||
|
| Abraham and Wamisho | 6 | 2 | 1 | 1 | 0 | 0 | 3 | – | 0 | |
| Azene et al | 55 | 48 | – | – | 9 | 35 | 45 | 51 | 5 | ||
| Bitew et al | 7 | – | 4 | 5 | 2 | 5 | 5 | – | 2 | ||
| Desalegn et al | 18 | – | 9 | 18 | 0 | 6 | 3 | – | 6 | ||
| Godebo et al | 107 | – | – | 77 | 8 | 8 | 81 | – | 35 | ||
| Guta et al | 12 | 11 | – | – | – | 8 | – | – | 6 | ||
| Hailu et al | NDA | – | 12 (22) | 17 (22) | 5 (22) | 8 (18) | 7 (17) | – | 5 (22) | ||
| Lema et al | 47 | 24 | 20 | 31 | 4 | – | 21 | – | 4 | ||
| Mama et al | 23 | – | – | 21 | 4 | 15 | 9 | – | 6 | ||
| Mengesha et al | 15 | 15 | 7 | 13 | 7 | 11 | – | 9 | 3 | ||
| Mohammed et al | 6 | – | – | 6 | 2 | 1 | 5 | – | 2 | ||
---, Not tested, NDA Number of isolates is different among antimicrobial agents tested as indicated in parenthesis of the corresponding rows, AMO Amoxicillin, AMP Ampicillin, AMC Amoxicillin-clavulanic acid, SXT Cotrimoxazole, CRO Ceftriaxone, CIP Ciprofloxacin, GEN Gentamicin, ERY Erythromycin
Fig. 2Forest plot depicting culture positivity among wound sample in Ethiopia
Fig. 3Forest plot showing subgroup analysis of culture positivity based on wound sources
Fig. 4Prevalence of S. aureus in wound samples
Fig. 5Pooled estimate of CoNS in wound samples in Ethiopia
Fig. 6Pooled estimates of E. coli in wound samples
Fig. 7Forest plot depicting the pooled prevalence of P. aeruginosa in wound samples
Fig. 8Pooled estimates of K. pneumoniae in wound samples
Fig. 9Pooled estimate of P. mirabilis
Pooled estimates of antimicrobial resistance among Gram-positive bacteria obtained from wound samples in Ethiopia
| Antimicrobial agents | Pooled estimates of resistant isolates (Proportion) | |||
|---|---|---|---|---|
|
|
| |||
| Pooled ES (95% CI) | I2 (%) | Pooled ES (95% CI) | I2 (%) | |
| AMO | 0.69 (0.50, 0.87) | 97.64 | 0.62 (0.34, 0.90) | 93.05 |
| AMC | 0.27 (0.16, 0.38) | 81.35 | NA | – |
| AMP | 0.76 (0.60, 0.92) | 97.17 | 0.72 (0.57,0.87) | 70.85 |
| CIP | 0.12 (0.08, 0.16) | 72.39 | 0.13 (0.04, 0.23) | 65.46 |
| CRO | 0.36 (0.17, 0.55) | 97.23 | 0.37 (0.19, 0.54) | 81.58 |
| SXT | 0.35 (0.20, 0.49) | 97.64 | 0.49 (0.31, 0.66) | 75.21 |
| ERY | 0.34 (0.22, 0.46) | 94.69 | 0.40 (0.20, 0.40) | 90.05 |
| GEN | 0.13 (0.08, 0.18) | 82.90 | 0.33 (0.17, 0.50) | 88.16 |
| MET | 0.49 (0.31, 0.68) | 94.50 | NA | – |
AMO Amoxicillin, AMP Ampicillin, AMC Amoxicillin-clavulanic acid, SXT Cotrimoxazole, CRO Ceftriaxone, CIP Ciprofloxacin, GEN Gentamicin, MET Methicillin, ERY Erythromycin, NA Not analyzed: CoNS, Coagulase negative Staphylococci
Pooled estimates of antimicrobial resistance among Gram-negative bacterial isolates obtained from wound samples in Ethiopia
| Antimicrobials | Pooled estimates of resistant isolates (Proportion) | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||
| ES (95% CI) | I2 (%) | ES (95% CI) | I2 (%) | ES (95% CI) | I2 (%) | ES (95% CI) | I2 (%) | |
| AMO | 0.73 (0.63, 0.83) | 55.70 | 0.87 (0.82, 0.92) | 0.00 | 0.90 (0.83, 0.97) | 43.97 | 0.75 (0.57, 0.93) | 86.81 |
|
| 0.57 (0.44, 0.70) | 74.51 | 0.77 (0.63, 0.91) | 63.67 | 0.67 (0.51, 0.83) | 78.01 | 0.45 (0.36, 0.54) | 19.01 |
| AMP | 0.84 (0.76, 0.91) | 75.08 | 0.95 (0.92, 0.99) | 0.00 | 0.88 (0.83, 0.93) | 24.27 | 0.78 (0.70, 0.85) | 39.67 |
| CIP | 0.27 (0.16, 0.37) | 86.99 | 0.16 (0.09, 0.24) | 87.63 | 0.29 (0.15, 0.42) | 85.50 | 0.12 (0.06, 0.19) | 73.68 |
| CRO | 0.45 (0.31, 0,60) | 89.81 | 0.58 (0.35, 0.82) | 95.86 | 0.57 (0.39, 0.75) | 92.32 | 0.43 (0.24, 0.63) | 94.04 |
| SXT | 0.53 (0.43, 0.64) | 75.91 | 0.76 (0.68, 0.85) | 51.82 | 0.64 (0.51, 0.77) | 76.58 | 0.56 (0.39, 0.72) | 88.19 |
| GEN | 0.24 (0.16, 0.33) | 93.09 | 0.18 (0.11, 0.26) | 66.47 | 0.37 (0.22, 0.52) | 89.66 | 0.21 (0.12, 0.30) | 74.31 |
AMO Amoxicillin, AMP Ampicillin, AMC Amoxicillin-clavulanic acid, SXT Cotrimoxazole, CRO Ceftriaxone, CIP Ciprofloxacin, GEN Gentamicin
Fig. 10Funnel plot showing publication bias of included studies